Exploring  ||| S:0 E:10 ||| VBG
the  ||| S:10 E:14 ||| DT
abyss  ||| S:14 E:20 ||| NN
of  ||| S:20 E:23 ||| IN
fibromyalgia  ||| S:23 E:36 ||| JJ
biomarkers  ||| S:36 E:47 ||| JJ
Many  ||| S:47 E:52 ||| JJ
researchers  ||| S:52 E:64 ||| NNS
are  ||| S:64 E:68 ||| VBP
studying  ||| S:68 E:77 ||| VBG
fibromyalgia  ||| S:77 E:90 ||| NN
to  ||| S:90 E:93 ||| TO
identify  ||| S:93 E:102 ||| VB
objective ||| S:102 E:111 ||| NN
,  ||| S:111 E:113 ||| ,
measurable  ||| S:113 E:124 ||| JJ
biomarkers  ||| S:124 E:135 ||| NN
that  ||| S:135 E:140 ||| WDT
may  ||| S:140 E:144 ||| MD
identify  ||| S:144 E:153 ||| VB
the  ||| S:153 E:157 ||| DT
patients ||| S:157 E:165 ||| NNS
,  ||| S:165 E:167 ||| ,
for  ||| S:167 E:171 ||| IN
the  ||| S:171 E:175 ||| DT
purpose  ||| S:175 E:183 ||| NN
of  ||| S:183 E:186 ||| IN
diagnosis  ||| S:186 E:196 ||| NN
or  ||| S:196 E:199 ||| CC
to  ||| S:199 E:202 ||| TO
measure  ||| S:202 E:210 ||| VB
the  ||| S:210 E:214 ||| DT
disease  ||| S:214 E:222 ||| NN
activity ||| S:222 E:230 ||| NN
.  ||| S:230 E:232 ||| .
The  ||| S:232 E:236 ||| DT
recent  ||| S:236 E:243 ||| JJ
literature  ||| S:243 E:254 ||| NN
proposes  ||| S:254 E:263 ||| VBZ
instrumental  ||| S:263 E:276 ||| JJ
or  ||| S:276 E:279 ||| CC
molecular  ||| S:279 E:289 ||| JJ
biomarkers ||| S:289 E:299 ||| NN
,  ||| S:299 E:301 ||| ,
but  ||| S:301 E:305 ||| CC
several  ||| S:305 E:313 ||| JJ
of  ||| S:313 E:316 ||| IN
these  ||| S:316 E:322 ||| DT
are  ||| S:322 E:326 ||| VBP
only  ||| S:326 E:331 ||| RB
useful  ||| S:331 E:338 ||| JJ
for  ||| S:338 E:342 ||| IN
research  ||| S:342 E:351 ||| NN
purposes ||| S:351 E:359 ||| NNS
.  ||| S:359 E:361 ||| .
Concentrated  ||| S:361 E:374 ||| JJ
efforts  ||| S:374 E:382 ||| NNS
to  ||| S:382 E:385 ||| TO
systematically  ||| S:385 E:400 ||| RB
evaluate  ||| S:400 E:409 ||| VB
additional  ||| S:409 E:420 ||| JJ
objective  ||| S:420 E:430 ||| NN
measures  ||| S:430 E:439 ||| NNS
in  ||| S:439 E:442 ||| IN
research  ||| S:442 E:451 ||| NN
trials  ||| S:451 E:458 ||| NNS
will  ||| S:458 E:463 ||| MD
be  ||| S:463 E:466 ||| VB
vital  ||| S:466 E:472 ||| JJ
for  ||| S:472 E:476 ||| IN
the  ||| S:476 E:480 ||| DT
ongoing  ||| S:480 E:488 ||| JJ
progress  ||| S:488 E:497 ||| NN
in  ||| S:497 E:500 ||| IN
outcome  ||| S:500 E:508 ||| NN
research  ||| S:508 E:517 ||| NN
and  ||| S:517 E:521 ||| CC
translation  ||| S:521 E:533 ||| NN
into  ||| S:533 E:538 ||| IN
clinical  ||| S:538 E:547 ||| JJ
practice ||| S:547 E:555 ||| NN
.  ||| S:555 E:557 ||| .
The  ||| S:557 E:561 ||| DT
aim  ||| S:561 E:565 ||| NN
of  ||| S:565 E:568 ||| IN
this  ||| S:568 E:573 ||| DT
review  ||| S:573 E:580 ||| NN
is  ||| S:580 E:583 ||| VBZ
a  ||| S:583 E:585 ||| DT
guided  ||| S:585 E:592 ||| JJ
tour  ||| S:592 E:597 ||| NN
of  ||| S:597 E:600 ||| IN
the  ||| S:600 E:604 ||| DT
specific  ||| S:604 E:613 ||| JJ
literature ||| S:613 E:623 ||| NN
.  ||| S:623 E:625 ||| .
